Management of KDIGO Stage I AKI in Cisplatin-Based Chemoradiation for Head and Neck SCC
Immediately hold cisplatin when KDIGO Stage I AKI develops during concurrent chemoradiation for squamous cell carcinoma of the neck, and do not resume until renal function returns to baseline. 1
Critical Decision Point: Cisplatin Continuation vs. Discontinuation
The FDA label for cisplatin explicitly states that "renal function must return to normal before another dose of cisplatin can be given" 1. This is non-negotiable. The drug label takes precedence over treatment completion goals, as cumulative renal toxicity is the major dose-limiting toxicity of cisplatin 1.
Immediate Management Steps
Hold all nephrotoxic agents immediately:
- Discontinue cisplatin until AKI resolves
- Stop NSAIDs, aminoglycosides, and other nephrotoxic medications 2
- Review and discontinue RAAS blockers (ACE inhibitors/ARBs) if present, as these significantly increase AKI risk (38% vs 21% in non-users) and worsen mortality in this population 3
Implement aggressive hydration protocol:
- Administer isotonic sodium chloride or sodium bicarbonate IV at 1-1.5 mL/kg/hour 2
- Target urine output >150 mL/hour for 6 hours post-exposure 2
- Consider extended at-home hydration (1L/12h for 1 week) if resuming cisplatin, as this reduces AKI rates from 30% to 24% 4
Monitor renal function closely:
- Check serum creatinine every 2-3 days until return to baseline
- Calculate creatinine clearance, not just serum creatinine 1
- Consider biomarkers (NGAL, KIM-1) for earlier detection of worsening injury 5
Treatment Modification Algorithm
If Renal Function Returns to Baseline:
Option 1 (Preferred): Resume high-dose cisplatin with enhanced nephroprotection
- Continue cisplatin 100 mg/m² every 3 weeks if baseline renal function restored 6
- Implement mannitol-based reduced-volume hydration protocol (reduces AKI from 74% to 54%) 7
- Extend post-treatment hydration to 1 week at home 4
Option 2: Switch to weekly cisplatin dosing
- Cisplatin 40 mg/m² weekly with radiation 6
- Important caveat: This is supported by limited evidence and should involve careful discussion of risks 6
- Still requires adequate hydration and monitoring
If Renal Function Does Not Return to Baseline:
Cisplatin is contraindicated - the FDA label explicitly states cisplatin is contraindicated in patients with pre-existing renal impairment 1
Switch to radiation alone:
- For high-risk postoperative patients unable to receive cisplatin, radiotherapy alone should be delivered without concurrent systemic therapy 6
- Do not substitute with:
Critical Risk Factors to Monitor
Patient-specific factors predicting worse outcomes:
- Female sex (92.6% AKI rate vs 60.5% in males) 7
- Low body cell mass (BCM/kg/m) - independent predictor of AKI 8
- Baseline hypertension, especially if on RAAS blockers 3
- Age >70 years 1
- Baseline low creatinine clearance 9
Common Pitfalls to Avoid
Do not continue cisplatin "to complete the planned dose" - this violates FDA labeling and risks irreversible renal failure 1
Do not switch to carboplatin - this has a strong recommendation against use in head/neck cancer chemoradiation 6
Do not rely solely on serum creatinine - it lacks sensitivity for early AKI detection; use creatinine clearance calculations 1
Do not use oral hydration alone - IV hydration is required for adequate nephroprotection 2
Do not consider amifostine - insufficient data support its routine use for cisplatin nephrotoxicity prevention 10
Outcome Prioritization
The priority hierarchy is:
- Prevent irreversible renal failure (mortality/morbidity concern)
- Complete radiation therapy (can be curative alone in many cases)
- Maximize safe cisplatin dose (only if renal function permits)
Completing the full cisplatin dose is less important than preventing permanent renal damage. Radiation alone can still provide meaningful disease control in head and neck SCC, whereas dialysis-dependent renal failure severely impacts quality of life and mortality 3.